Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1999 Apr;89(4):561–563. doi: 10.2105/ajph.89.4.561

The effects on fetal development of high alpha-fetoprotein and maternal smoking.

S Heinonen 1, M Ryynänen 1, P Kirkinen 1
PMCID: PMC1508907  PMID: 10191802

Abstract

OBJECTIVES: This study determined the risk of impaired fetal growth resulting from the interaction between maternal smoking during pregnancy and unexplained elevated concentrations of maternal serum alpha-fetoprotein (MSAFP). METHODS: This observational study involved 123 pregnant smokers with unexplained second-trimester elevated concentrations of MSAFP, 827 smokers with normal levels, and 471 nonsmokers with raised levels. RESULTS: By logistic regression, coincident smoking and elevated MSAFP levels were found to be associated with increases in the low basic risks of prematurity, small-for-gestational-age births, low birthweight, and need for neonatal care. CONCLUSIONS: Maternal smoking has an adverse effect on fetal development in pregnancies with unexplained elevated MSAFP concentrations. Such pregnancies merit close surveillance.

Full text

PDF
561

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brock D. J., Barron L., Jelen P., Watt M., Scrimgeour J. B. Maternal serum-alpha-fetoprotein measurements as an early indicator of low birth-weight. Lancet. 1977 Aug 6;2(8032):267–268. doi: 10.1016/s0140-6736(77)90952-7. [DOI] [PubMed] [Google Scholar]
  2. Brooke O. G., Anderson H. R., Bland J. M., Peacock J. L., Stewart C. M. Effects on birth weight of smoking, alcohol, caffeine, socioeconomic factors, and psychosocial stress. BMJ. 1989 Mar 25;298(6676):795–801. doi: 10.1136/bmj.298.6676.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burton B. K., Dillard R. G. Outcome in infants born to mothers with unexplained elevations of maternal serum alpha-fetoprotein. Pediatrics. 1986 Apr;77(4):582–586. [PubMed] [Google Scholar]
  4. Burton B. K. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol. 1988 Nov;72(5):709–713. [PubMed] [Google Scholar]
  5. Chard T., Rice A., Kitau M. J., Hird V., Grudzinskas J. G., Nysenbaum A. M. Mid-trimester levels of alphafetoprotein in the screening of low birthweight. Br J Obstet Gynaecol. 1986 Jan;93(1):36–38. doi: 10.1111/j.1471-0528.1986.tb07810.x. [DOI] [PubMed] [Google Scholar]
  6. Cnattingius S., Forman M. R., Berendes H. W., Graubard B. I., Isotalo L. Effect of age, parity, and smoking on pregnancy outcome: a population-based study. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):16–21. doi: 10.1016/s0002-9378(12)90878-9. [DOI] [PubMed] [Google Scholar]
  7. Dyer S. N., Burton B. K., Nelson L. H. Elevated maternal serum alpha-fetoprotein levels and oligohydramnios: poor prognosis for pregnancy outcome. Am J Obstet Gynecol. 1987 Aug;157(2):336–339. doi: 10.1016/s0002-9378(87)80164-3. [DOI] [PubMed] [Google Scholar]
  8. Heinonen S., Ryynänen M., Kirkinen P., Penttilä I., Syrjänen K., Seppälä M., Saarikoski S. Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease. Prenat Diagn. 1996 Mar;16(3):207–213. doi: 10.1002/(SICI)1097-0223(199603)16:3<207::AID-PD834>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  9. Konchak P. S., Bernstein I. M., Capeless E. L. Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum alpha-fetoprotein levels. Am J Obstet Gynecol. 1995 Oct;173(4):1115–1119. doi: 10.1016/0002-9378(95)91336-x. [DOI] [PubMed] [Google Scholar]
  10. Kramer M. S. Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ. 1987;65(5):663–737. [PMC free article] [PubMed] [Google Scholar]
  11. Milunsky A., Jick S. S., Bruell C. L., MacLaughlin D. S., Tsung Y. K., Jick H., Rothman K. J., Willett W. Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol. 1989 Aug;161(2):291–297. doi: 10.1016/0002-9378(89)90501-2. [DOI] [PubMed] [Google Scholar]
  12. Penttilä I. M., Ryynänen M., Hämäläinen E., Puhakainen E., Savolainen K. Quality specifications for S-AFP and S-HCG-beta determinations for screening of fetal abnormalities. Ups J Med Sci. 1993;98(3):375–380. doi: 10.3109/03009739309179335. [DOI] [PubMed] [Google Scholar]
  13. Robinson L., Grau P., Crandall B. F. Pregnancy outcomes after increasing maternal serum alpha-fetoprotein levels. Obstet Gynecol. 1989 Jul;74(1):17–20. [PubMed] [Google Scholar]
  14. Sexton M., Hebel J. R. A clinical trial of change in maternal smoking and its effect on birth weight. JAMA. 1984 Feb 17;251(7):911–915. [PubMed] [Google Scholar]
  15. Wen S. W., Goldenberg R. L., Cutter G. R., Hoffman H. J., Cliver S. P., Davis R. O., DuBard M. B. Smoking, maternal age, fetal growth, and gestational age at delivery. Am J Obstet Gynecol. 1990 Jan;162(1):53–58. doi: 10.1016/0002-9378(90)90819-s. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES